Long-term prognosis in patients undergoing redo-isolated aortic valve replacement.
Aleksander DokollariGianluca TorregrossaSerge SicouriMatteo CameliGiulia Elena MandoliStephanie KjelstromEdvin PriftiAltin VeshtiMassimo BonacchiSandro GelsominoPublished in: Future cardiology (2023)
Aim: To evaluate clinical outcomes after redo aortic valve replacement (AVR) with sutured valves, versus valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), versus sutureless valves. Methods: We identified 113 consecutive patients undergoing redo AVR with either ViV-TAVR, redo-sutured and redo-sutureless valves between August 2010 to March 2020. Heart-team made the decision whether patient should undergo redo-sutureless versus ViV-TAVR, versus redo-sutured AVR. Results: Preoperatively, redo-sutured (n = 57), ViV-TAVR (n = 31) and redo-sutureless (n = 25) patients were compared. Postoperatively, after propensity-adjustment analysis, the redo surgical aortic valve replacement group had a higher incidence of new postoperative atrial fibrillation (POAF; p = 0.04) compared with redo-sutureless group. Follow-up outcomes analysis did not show differences among groups. Conclusion: Patients undergoing redo-sutureless AVR experienced a higher incidence of POAF compared with patients undergoing redo-sutured.
Keyphrases
- aortic valve replacement
- aortic stenosis
- aortic valve
- transcatheter aortic valve replacement
- ejection fraction
- transcatheter aortic valve implantation
- patients undergoing
- left ventricular
- atrial fibrillation
- coronary artery disease
- risk factors
- end stage renal disease
- chronic kidney disease
- type diabetes
- metabolic syndrome
- adipose tissue
- peritoneal dialysis
- quality improvement
- skeletal muscle
- acute coronary syndrome